LOGIN
E. coli-derived rhBMP-2 offers similar fusion success to AIBG in posterolateral lumbar fusion
January 2018
E. coli-derived rhBMP-2 offers similar fusion success to AIBG in posterolateral lumbar fusion
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Efficacy of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in posterolateral lumbar fusion: an open, active-controlled, randomized, multicenter trial
Spine J. 2017 Dec;17(12):1866-1874Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
100 patients scheduled for posterolateral fusion due to severe spinal stenosis, grade 1 spondylolisthesis, or spondylolysis were randomized to graft material of either Escherichia coli-derived recombinant human bone morphogenetic protein-2 (rhBMP-2) in a hydroxyapatite carrier or an autologous iliac crest bone graft. Patients were assessed primarily for fusion success on CT at 12 and 24 weeks. Sec...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Join the Conversation
Please Login or Join to leave comments.